Table 4.
Cox proportional univariate and multivariate analysis of variables correlated with time to progression.
| Variables | Univariate | Multivariate | ||
|---|---|---|---|---|
| HR (95% CI) | p Value | HR (95% CI) | p Value | |
| Age < 51 | 0.952 (0.597–1.517) | 0.835 | ||
| WHO PS < 2 | 0.89 (0.53–1.49) | 0.680 | ||
| Comorbid Illness | 0.78 (0.55–1.10) | 0.170 | ||
| History of early-Stage Breast cancer | 0.790 (0. 524–1.191) | 0.260 | ||
| Secondary Endocrine Resistance | 0.728 (0.493–1.077) | 0.112 | 0.717 (0.480–1.071) | 0.104 |
| Lack of chemotherapy prior to Fulvestrant | 0.710 (0.506–0.996) | 0.047 | 0.802 (0.540–1.191) | 0.274 |
| Non-Visceral Metastasis | 0.783 (0.557–1.099) | 0.158 | 0.701 (0.495–0.994) | 0.046 |
| ≤2 previous therapies | 0.672 (0.480–0.940) | 0.020 | 0.775 (0.517–1.161) | 0.216 |
| Combination therapy | 0.714 (0.462–1.104) | 0.130 | 0.745 (0.468–1.187) | 0.216 |
| Time to Fulvestrant | 0.732 (0.523–1.024) | 0.068 | ||